Cationic Lipid Structure for Stable Nucleic Acid Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cationic lipid compositions for delivering biologically active substances face challenges in safety, efficacy, and specificity, with increased complexity leading to potential toxicity and limited clinical application, particularly for nucleic acid therapeutics.
Innovation Solution
Development of a novel cationic lipid compound of formula (I) and compositions containing it, which are designed to enhance transfection efficiency, reduce cytotoxicity, and improve expression levels of nucleic acids, proteins, and small molecule drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If complex lipid nanoparticle compositions are used to deliver nucleic acids, then delivery efficacy is improved, but toxicity increases and safety worsens
Solution Approach 1:
The patent extracts and eliminates unnecessary complex components from lipid nanoparticle formulations, focusing on essential cationic lipids with specific structural features (amino groups with pKa 6.0-8.0, specific chain lengths and configurations) to achieve effective nucleic acid delivery without the toxicity associated with complex multi-component formulations
Solution Approach 2:
The patent optimizes critical parameters of cationic lipids including pKa values (6.0-8.0), chain lengths (C12-C22), and structural configurations to achieve the optimal balance between delivery efficacy and reduced toxicity, eliminating the need for preadministration of steroids and antihistamines
2Reliability
If multiple lipid components are combined in LNP formulations, then delivery capability is enhanced, but production complexity increases
Solution Approach 1:
The patent simplifies production by extracting and eliminating unnecessary lipid components from complex LNP formulations, retaining only the essential cationic lipid with specific structural features that provide both delivery capability and reduced complexity
Solution Approach 2:
The patent designs a universal cationic lipid structure that performs multiple functions simultaneously: complex formation with nucleic acids, cellular uptake facilitation, and endosomal escape, eliminating the need for multiple specialized components in the formulation
3Productivity
If cationic lipids with high transfection efficiency are used, then nucleic acid delivery is improved, but cytotoxicity increases
Solution Approach 1:
The patent optimizes the pKa parameter to 6.0-8.0 and chain length to C12-C22 for cationic lipids, achieving high transfection efficiency while minimizing cytotoxicity through precise parameter control rather than using highly aggressive cationic structures
Solution Approach 2:
The patent introduces specific structural features at localized positions within the cationic lipid molecule (amino group positioning, chain length variations, cyclic vs. linear configurations) to enhance transfection efficiency at the molecular level while maintaining overall biocompatibility
Data Source
AI summary
The present invention provides a cationic lipid compound with high efficiency, low toxicity and stable expression, which is a compound of formula (I) or an N-oxide, a solvate, a pharmaceutically acceptable salt or a stereoisomer thereof Further provided are a composition comprising the described compound and a use thereof in delivering a therapeutic or prophylactic agent.